The development of vaccines targeting NS proteins abolishes the risk of individuals developing severe flaviviral disease due to ADE, with NS5 being a notably promising vaccine target due to its ability to elicit an immunodominant immune response [181]. This evidence concerns the gene RAF1 and acute disseminated encephalomyelitis.